Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:acquisitionYear |
2008
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:focus |
oncology
inflammatory diseases |
| gptkbp:foundedIn |
1993
|
| gptkbp:founder |
gptkb:Mark_Levin
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Millennium Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Velcade
|
| gptkbp:numberOfEmployees |
approximately 1,000 (at time of acquisition)
|
| gptkbp:parentCompany |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:researchArea |
drug discovery
cancer therapeutics |
| gptkbp:status |
gptkb:subsidiary
|
| gptkbp:stockSymbol |
MLNM
|
| gptkbp:website |
https://www.millennium.com/
|
| gptkbp:bfsParent |
gptkb:Takeda
gptkb:Takeda_(Japan) |
| gptkbp:bfsLayer |
6
|